NYSEAMERICAN:NBY NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis $0.73 +0.01 (+1.39%) (As of 11/14/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest About NovaBay Pharmaceuticals Stock (NYSEAMERICAN:NBY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NBY alerts:Sign Up Key Stats Today's Range$0.70▼$0.7550-Day Range N/A52-Week Range$0.36▼$12.08Volume76,055 shsAverage Volume994,079 shsMarket Capitalization$3.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. It sells its products through the company's web stores, third-party online retailers and distribution partners. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.Read More… Central Bank Abandons USD (Ad)Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. Click here now to get your free 'Protect Your Wealth' Guide. NovaBay Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks9th Percentile Overall ScoreNBY MarketRank™: NovaBay Pharmaceuticals scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for NovaBay Pharmaceuticals. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NovaBay Pharmaceuticals are expected to grow in the coming year, from ($2.54) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NovaBay Pharmaceuticals is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NovaBay Pharmaceuticals is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovaBay Pharmaceuticals has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.15% of the outstanding shares of NovaBay Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverNovaBay Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NovaBay Pharmaceuticals has recently increased by 4,169.83%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNovaBay Pharmaceuticals does not currently pay a dividend.Dividend GrowthNovaBay Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted18.15% of the outstanding shares of NovaBay Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverNovaBay Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NovaBay Pharmaceuticals has recently increased by 4,169.83%, indicating that investor sentiment is decreasing significantly. News and Social Media1.8 / 5News SentimentN/A News SentimentNovaBay Pharmaceuticals has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for NovaBay Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for NBY on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NovaBay Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.30% of the stock of NovaBay Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 1.34% of the stock of NovaBay Pharmaceuticals is held by institutions.Read more about NovaBay Pharmaceuticals' insider trading history. Receive NBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address NBY Stock News Headlines**NovaBay Pharmaceuticals Enters into Amendment to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals**November 7, 2024 | americanbankingnews.comNovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLCOctober 29, 2024 | finance.yahoo.comCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. November 14, 2024 | True Gold Republic (Ad)NovaBay Pharmaceuticals receives unsolicited offer from Refresh AcquisitionsOctober 29, 2024 | msn.comNovaBay Pharmaceuticals (AMEX:NBY) Stock, Short Interest ReportSeptember 26, 2024 | benzinga.comNovaBay Pharmaceuticals (AMEX:NBY) Stock Quotes, Forecast and News SummarySeptember 26, 2024 | benzinga.comWhat's Going On With NovaBay Pharmaceuticals Shares Friday?September 20, 2024 | msn.comNovaBay Pharmaceuticals, Inc. (B9P0.F)August 20, 2024 | finance.yahoo.comSee More Headlines NBY Stock Analysis - Frequently Asked Questions How have NBY shares performed this year? NovaBay Pharmaceuticals' stock was trading at $0.1802 at the start of the year. Since then, NBY stock has increased by 294.1% and is now trading at $0.7101. View the best growth stocks for 2024 here. How were NovaBay Pharmaceuticals' earnings last quarter? NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) posted its quarterly earnings results on Thursday, November, 11th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts' consensus estimates of ($1.40) by $0.35. The biopharmaceutical company had revenue of $1.84 million for the quarter. NovaBay Pharmaceuticals had a negative trailing twelve-month return on equity of 146.20% and a negative net margin of 79.70%. When did NovaBay Pharmaceuticals' stock split? NovaBay Pharmaceuticals shares reverse split on Wednesday, November 16th 2022. The 1-35 reverse split was announced on Wednesday, November 16th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of NovaBay Pharmaceuticals? Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NovaBay Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that NovaBay Pharmaceuticals investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), Tesla (TSLA) and TherapeuticsMD (TXMD). Company Calendar Last Earnings11/11/2021Today11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:NBY CUSIPN/A CIK1389545 Webnovabay.com Phone(510) 899-8800Fax510-474-1577Employees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($9.9465) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,610,000.00 Net Margins-79.70% Pretax Margin-79.70% Return on Equity-146.20% Return on Assets-69.63% Debt Debt-to-Equity RatioN/A Current Ratio1.85 Quick Ratio1.25 Sales & Book Value Annual Sales$14.40 million Price / Sales0.21 Cash FlowN/A Price / Cash FlowN/A Book Value$1.53 per share Price / Book0.48Miscellaneous Outstanding Shares4,210,000Free Float4,160,000Market Cap$3.06 million OptionableNot Optionable Beta2.82 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NYSEAMERICAN:NBY) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NovaBay Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.